Powell’s speech, Nvidia’s chips, Meta deal - what’s moving markets
SAN FRANCISCO - Hims & Hers Health, Inc. (NYSE: HIMS), a prominent health and wellness platform, has announced the appointment of Nader Kabbani as its new Chief Operations Officer, effective May 19, 2025. Kabbani, an experienced leader with a notable tenure at Amazon, is set to enhance the company’s operations amid its expansion to provide personalized care on a larger scale.
With a background that includes spearheading Amazon’s entry into the pharmacy sector through the acquisition of PillPack and launching Amazon Pharmacy, Kabbani is recognized for his ability to scale operations. His contributions at Amazon also encompassed the development of operational systems for Amazon Logistics, Amazon Flex, and their digital media services. Kabbani’s leadership extended to managing Amazon’s global COVID-19 Vaccination Task Force, which played a crucial role in vaccinating a vast network of employees and affiliates.
Andrew Dudum, CEO and founder of Hims & Hers, expressed confidence in Kabbani’s capabilities to innovate the healthcare experience. Dudum highlighted Kabbani’s central role in meeting the growing demand for accessible, personalized healthcare solutions.
Kabbani shared his enthusiasm for the opportunity to expand the company’s infrastructure that aims to provide fast, reliable, and high-quality care. He underscored the potential to redefine healthcare for today’s consumers through the scale-up of operations.
Hims & Hers is known for its consumer-centric model of health and wellness, focusing on personalized care. The company continues to invest in technology, infrastructure, and services to make personalized healthcare more accessible to its increasing subscriber base.
The information is based on a press release statement from Hims & Hers Health, Inc.
In other recent news, Hims & Hers Health, Inc. has been in the spotlight due to several key developments. The company recently announced a partnership with Novo Nordisk, allowing them to offer the weight loss drug Wegovy through NovoCare Pharmacy at a monthly price of $599, which includes clinical support and nutritional guidance. Analysts have responded with varied ratings: Piper Sandler maintained a Neutral rating with a $35 target, citing uncertainties in the weight loss sector. TD Cowen held a Hold rating with a $30 target, highlighting competition and economic risks. BofA Securities raised its price target to $26 but retained an Underperform rating, noting potential benefits from the partnership but expressing concerns about consumer trends. Morgan Stanley reaffirmed an Equalweight rating with a $40 target, emphasizing the partnership’s role in addressing legal concerns. Meanwhile, Citi maintained a Sell rating with a $25 target, suggesting the partnership could make Hims & Hers’ revenue goals more achievable. These developments reflect the company’s strategic moves and the diverse analyst opinions on its future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.